Nektar Therapeutics (STU:ITH) Short Percentage of Float

View and export this data going back to 2013. Start your Free Trial

What is Nektar Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Nektar Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Nektar Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Short Percentage of Float falls into.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (STU:ITH) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

NKTR:USA 0UNL:UK ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Nektar Therapeutics Headlines

No Headlines